AhR signalling and dioxin toxicity

Toxicology Letters

Volumn 230, Issue 2, 2014, Pages 225-233

  Sorg, Olivier ^a  

^a Swiss Centre for Applied Human Toxicology   (Switzerland)

Author keywords

AhR; Cell signalling; Dioxin; Skin; TCDD; Toxicity

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; AROMATIC HYDROCARBON RECEPTOR; DIOXIN; POLYCHLORINATED BIPHENYL; POLYCHLORINATED DIBENZODIOXIN; POLYCHLORINATED DIBENZOFURAN;

ACUTE TOXICITY; BIOASSAY; CARCINOGENIC ACTIVITY; CARCINOGENICITY; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; CHLORACNE; HAMARTOMA; HUMAN; LONG TERM EXPOSURE; NONHUMAN; REPRODUCTIVE TOXICITY; REVIEW; SIGNAL TRANSDUCTION; SKIN; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; NEOPLASM; PHYSIOLOGY; REPRODUCTION; TOXICITY;

ANIMALS; CHLORACNE; HUMANS; NEOPLASMS; RECEPTORS, ARYL HYDROCARBON; REPRODUCTION; SIGNAL TRANSDUCTION; SKIN; TETRACHLORODIBENZODIOXIN;

EID: 84907176547     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2013.10.039     Document Type: Review

References (94)

1. Abel J., Haarmann-Stemmann T. An introduction to the molecular basics of aryl hydrocarbon receptor biology. Biol. Chem. 2010, 391:1235-1248.
2. Anonymous Indole-3-carbinol. Monograph. Altern. Med. Rev. 2005, 10:337-342.
3. Assennato G., Cervino D., Emmett E.A., Longo G., Merlo F. Follow-up of subjects who developed chloracne following TCDD exposure at Seveso. Am. J. Ind. Med. 1989, 16:119-125.
4. Audebert M., Riu A., Jacques C., Hillenweck A., Jamin E.L., Zalko D., Cravedi J.P. Use of the gammaH2AX assay for assessing the genotoxicity of polycyclic aromatic hydrocarbons in human cell lines. Toxicol. Lett. 2010, 199:182-192.
5. Aylward L.L., Brunet R.C., Carrier G., Hays S.M., Cushing C.A., Needham L.L., Patterson D.G., Gerthoux P.M., Brambilla P., Mocarelli P. Concentration-dependent TCDD elimination kinetics in humans: toxicokinetic modeling for moderately to highly exposed adults from Seveso, Italy, and Vienna, Austria, and impact on dose estimates for the NIOSH cohort. J. Exposure Anal. Environ. Epidemiol. 2005, 15:51-65.
6. Behnia K., Bhatia S., Jastromb N., Balis U., Sullivan S., Yarmush M., Toner M. Xenobiotic metabolism by cultured primary porcine hepatocytes. Tissue Eng. 2000, 6:467-479.
7. Beischlag T.V., Luis Morales J., Hollingshead B.D., Perdew G.H. The aryl hydrocarbon receptor complex and the control of gene expression. Crit. Rev. Eukaryot. Gene Expression 2008, 18:207-250.
8. Bertazzi P.A., Consonni D., Bachetti S., Rubagotti M., Baccarelli A., Zocchetti C., Pesatori A.C. Health effects of dioxin exposure: a 20-year mortality study. Am. J. Epidemiol. 2001, 153:1031-1044.
9. Bock K.W., Kohle C. The mammalian aryl hydrocarbon (Ah) receptor: from mediator of dioxin toxicity toward physiological functions in skin and liver. Biol. Chem. 2009, 390:1225-1235.
10. Boffetta P., Mundt K.A., Adami H.O., Cole P., Mandel J.S. TCDD and cancer: a critical review of epidemiologic studies. Crit. Rev. Toxicol. 2011, 41:622-636.
11. Bohonowych J.E., Denison M.S. Persistent binding of ligands to the aryl hydrocarbon receptor. Toxicol. Sci. 2007, 98:99-109.
12. Boussemart L., Routier E., Mateus C., Opletalova K., Sebille G., Kamsu-Kom N., Thomas M., Vagner S., Favre M., Tomasic G., Wechsler J., Lacroix L., Robert C. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann. Oncol. 2013, 24:1691-1697.
13. Boverhof D.R., Kwekel J.C., Humes D.G., Burgoon L.D., Zacharewski T.R. Dioxin induces an estrogen-like, estrogen receptor-dependent gene expression response in the murine uterus. Mol. Pharmacol. 2006, 69:1599-1606.
14. Brookes P. Mutagenicity of polycyclic aromatic hydrocarbons. Mutat. Res. 1977, 39:257-283.
15. Butts M., Jatoi A. Rash from newer cancer agents: why do we still not have effective therapy for palliation and/or prevention?. J. Support. Oncol. 2010, 8:162-163.
16. Cole P., Trichopoulos D., Pastides H., Starr T., Mandel J.S. Dioxin and cancer: a critical review. Regul. Toxicol. Pharmacol. 2003, 38:378-388.
17. Connor K.T., Harris M.A., Edwards M.R., Budinsky R.A., Clark G.C., Chu A.C., Finley B.L., Rowlands J.C. AH receptor agonist activity in human blood measured with a cell-based bioassay: evidence for naturally occurring AH receptor ligands in vivo. J. Exposure Sci. Environ. Epidemiol. 2008, 18:369-380.
18. De Galvez Aranda M.V., Sanchez P.S., Alonso Corral M.J., Bosch Garcia R.J., Gallardo M.A., Herrera Ceballos E. Acneiform eruption caused by amineptine. A case report and review of the literature. J. Eur. Acad. Dermatol. Venereol. 2001, 15:337-339.
19. de Waard P.W., Peijnenburg A.A., Baykus H., Aarts J.M., Hoogenboom R.L., van Schooten F.J., de Kok T.M. A human intervention study with foods containing natural Ah-receptor agonists does not significantly show AhR-mediated effects as measured in blood cells and urine. Chem. Biol. Interact. 2008, 176:19-29.
20. Garattini S. Pharmacology of amineptine, an antidepressant agent acting on the dopaminergic system: a review. Int. Clin. Psychopharmacol. 1997, 12(Suppl 3):S15-S19.
21. Gawkrodger D.J., Harris G., Bojar R.A. Chloracne in seven organic chemists exposed to novel polycyclic halogenated chemical compounds (triazoloquinoxalines). Br. J. Dermatol. 2009, 161:939-943.
22. Geusau A., Tschachler E., Meixner M., Papke O., Stingl G., McLachlan M. Cutaneous elimination of 2,3,7,8-tetrachlorodibenzo-p-dioxin. Br. J. Dermatol. 2001, 145:938-943.
23. Geyer H.J., Scheunert I., Rapp K., Gebefugi I., Steinberg C., Kettrup A. The relevance of fat content in toxicity of lipophilic chemicals to terrestrial animals with special reference to dieldrin and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Ecotoxicol. Environ. Saf. 1993, 26:45-60.
24. Geyer H.J., Scheuntert I., Rapp K., Kettrup A., Korte F., Greim H., Rozman K. Correlation between acute toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and total body fat content in mammals. Toxicology 1990, 65:97-107.
25. Guyot E., Chevallier A., Barouki R., Coumoul X. The AhR twist: ligand-dependent AhR signaling and pharmaco-toxicological implications. Drug Discovery Today 2013, 18:479-486.
26. Hahn M.E. Aryl hydrocarbon receptors: diversity and evolution. Chem. Biol. Interact. 2002, 141:131-160.
27. Hayes J.D., Dinkova-Kostova A.T., McMahon M. Cross-talk between transcription factors AhR and Nrf2: lessons for cancer chemoprevention from dioxin. Toxicol. Sci. 2009, 111:199-201.
28. Heiden T.K., Carvan M.J, Hutz R.J. Inhibition of follicular development, vitellogenesis, and serum 17beta-estradiol concentrations in zebrafish following chronic, sublethal dietary exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol. Sci. 2006, 90:490-499.
29. Hu W., Sorrentino C., Denison M.S., Kolaja K., Fielden M.R. Induction of cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro. Mol. Pharmacol. 2007, 71:1475-1486.
30. IARC IARC Monograph on the Evaluation of Carcinogenic Risks to Humans: Polychlorinated Dibenzo-para-dioxins and Polychlorinated Dibenzofurans 1997, 69:33-343. IARC, Lyon.
31. Ishimura R., Kawakami T., Ohsako S., Nohara K., Tohyama C. Suppressive effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on vascular remodeling that takes place in the normal labyrinth zone of rat placenta during late gestation. Toxicol. Sci. 2006, 91:265-274.
32. Jeffery E.H., Araya M. Physiological effects of broccoli consumption. Phytochem. Rev. 2009, 8:283-298.
33. Jia S., Hu C. Pharmacological effects of rutaecarpine as a cardiovascular protective agent. Molecules 2010, 15:1873-1881.
34. Ju Q., Zouboulis C.C., Xia L. Environmental pollution and acne: chloracne. Dermatoendocrinology 2009, 1:125-128.
35. Kitajima M., Khan K.N., Fujishita A., Masuzaki H., Koji T., Ishimaru T. Expression of the arylhydrocarbon receptor in the peri-implantation period of the mouse uterus and the impact of dioxin on mouse implantation. Arch. Histol. Cytol. 2004, 67:465-474.
36. Ko¨hle C., Bock K.W. Coordinate regulation of Phase I and II xenobiotic metabolisms by the Ah receptor and Nrf2. Biochem. Pharmacol. 2007, 73:1853-1862.
37. Kohn M.C. Biochemical mechanisms and cancer risk assessment models for dioxin. Toxicology 1995, 102:133-138.
38. Lai K.P., Wong M.H., Wong C.K. Modulation of AhR-mediated CYP1A1 mRNA and EROD activities by 17beta-estradiol and dexamethasone in TCDD-induced H411E cells. Toxicol. Sci. 2004, 78:41-49.
39. Lee S.H., Son J.K., Jeong B.S., Jeong T.C., Chang H.W., Lee E.S., Jahng Y. Progress in the studies on rutaecarpine. Molecules 2008, 13:272-300.
40. Li W., Wu W.Z., Xu Y., Li L., Schramm K.W., Kettrup A. Measuring TCDD equivalents in environmental samples with the micro-EROD assay: comparison with HRGC/HRMS data. Bull. Environ. Contam. Toxicol. 2002, 68:111-117.
41. Ma C., Marlowe J.L., Puga A. The aryl hydrocarbon receptor at the crossroads of multiple signaling pathways. EXS 2009, 99:231-257.
42. Malavia J., Abalos M., Santos F.J., Abad E., Rivera J., Galceran M.T. Ion-trap tandem mass spectrometry for the analysis of polychlorinated dibenzo-p-dioxins, dibenzofurans, and dioxin-like polychlorinated biphenyls in food. J. Agric. Food Chem. 2007, 55:10531-10539.
43. Mastrangelo G., Fadda E., Marzia V. Polycyclic aromatic hydrocarbons and cancer in man. Environ. Health Perspect. 1996, 104:1166-1170.
44. McIntosh B.E., Hogenesch J.B., Bradfield C.A. Mammalian Per-Arnt-Sim proteins in environmental adaptation. Annu. Rev. Physiol. 2010, 72:625-645.
45. McKillop D., Case D.E. Mutagenicity, carcinogenicity and toxicity of beta-naphthoflavone, a potent inducer of P448. Biochem. Pharmacol. 1991, 41:1-7.
46. Mimura J., Fujii-Kuriyama Y. Functional role of AhR in the expression of toxic effects by TCDD. Biochim. Biophys. Acta 2003, 1619:263-268.
47. Mocarelli P., Gerthoux P.M., Ferrari E., Patterson D.G., Kieszak S.M., Brambilla P., Vincoli N., Signorini S., Tramacere P., Carreri V., Sampson E.J., Turner W.E., Needham L.L. Paternal concentrations of dioxin and sex ratio of offspring. Lancet 2000, 355:1858-1863.
48. Mocarelli P., Gerthoux P.M., Patterson D.G., Milani S., Limonta G., Bertona M., Signorini S., Tramacere P., Colombo L., Crespi C., Brambilla P., Sarto C., Carreri V., Sampson E.J., Turner W.E., Needham L.L. Dioxin exposure, from infancy through puberty, produces endocrine disruption and affects human semen quality. Environ. Health Perspect. 2008, 116:70-77.
49. Moglich A., Ayers R.A., Moffat K. Structure and signaling mechanism of Per-ARNT-Sim domains. Structure 2009, 17:1282-1294.
50. Murray I.A., Perdew G.H. Omeprazole stimulates the induction of human insulin-like growth factor binding protein-1 through aryl hydrocarbon receptor activation. J. Pharmacol. Exp. Ther. 2008, 324:1102-1110.
51. Nardone B., Nicholson K., Newman M., Guitart J., Gerami P., Talarico N., Yang X.J., Rademaker A., West D.P., Lacouture M.E. Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients. Clin. Cancer Res. 2010, 16:4452-4460.
52. Niittynen M., Simanainen U., Syrjala P., Pohjanvirta R., Viluksela M., Tuomisto J., Tuomisto J.T. Differences in acute toxicity syndromes of 2,3,7,8-tetrachlorodibenzo-p-dioxin and 1,2,3,4,7,8-hexachlorodibenzo-p-dioxin in rats. Toxicology 2007, 235:39-51.
53. Ohtake F., Takeyama K., Matsumoto T., Kitagawa H., Yamamoto Y., Nohara K., Tohyama C., Krust A., Mimura J., Chambon P., Yanagisawa J., Fujii-Kuriyama Y., Kato S. Modulation of oestrogen receptor signalling by association with the activated dioxin receptor. Nature 2003, 423:545-550.
54. Paguio A., Stecha P., Wood K.V., Fan F. Improved dual-luciferase reporter assays for nuclear receptors. Curr. Chem. Genomics 2010, 4:43-49.
55. Passarini B., Infusino S.D., Kasapi E. Chloracne: still cause for concern. Dermatology 2010, 221:63-70.
56. Poland A., Knutson J.C. 2,3,7,8-tetrachlorodibenzo-p-dioxin and related halogenated aromatic hydrocarbons: examination of the mechanism of toxicity. Annu. Rev. Pharmacol. Toxicol. 1982, 22:517-554.
57. Poland A., Palen D., Glover E. Tumour promotion by TCDD in skin of HRS/J hairless mice. Nature 1982, 300:271-273.
58. Puga A., Ma C., Marlowe J.L. The aryl hydrocarbon receptor cross-talks with multiple signal transduction pathways. Biochem. Pharmacol. 2009, 77:713-722.
59. Quintana F.J. The aryl hydrocarbon receptor: a molecular pathway for the environmental control of the immune response. Immunology 2013, 138:183-189.
60. Quintana F.J., Basso A.S., Iglesias A.H., Korn T., Farez M.F., Bettelli E., Caccamo M., Oukka M., Weiner H.L. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008, 453:65-71.
61. Ramirez J.M., Brembilla N.C., Sorg O., Chicheportiche R., Matthes T., Dayer J.M., Saurat J.H., Roosnek E., Chizzolini C. Activation of the aryl hydrocarbon receptor reveals distinct requirements for IL-22 and IL-17 production by human T helper cells. Eur. J. Immunol. 2010, 40:2450-2459.
62. Ramot Y., Nyska A., Lieuallen W., Maly A., Flake G., Kissling G.E., Brix A., Malarkey D.E., Hooth M.J. Inflammatory and chloracne-like skin lesions in B6C3F1 mice exposed to 3,3',4,4'-tetrachloroazobenzene for 2 years. Toxicology 2009, 265:1-9.
63. Rifkind A.B. CYP1A in TCDD toxicity and in physiology-with particular reference to CYP dependent arachidonic acid metabolism and other endogenous substrates. Drug Metab. Rev. 2006, 38:291-335.
64. Rinderknecht J.D., Goldinger S.M., Rozati S., Kamarashev J., Kerl K., French L.E., Dummer R., Belloni B. RASopathic skin eruptions during vemurafenib therapy. PLoS One 2013, 8:e58721.
65. Ryan J.J. Human poisonings and the Yushchenko case. Organohalogen Compd. 2005, 67:1699-1701.
66. Saurat J.H., Kaya G., Saxer-Sekulic N., Pardo B., Becker M., Fontao L., Mottu F., Carraux P., Pham X., Barde C., Fontao F., Zennegg M., Schmid P., Schaad O., Descombes P., Sorg O. The cutaneous lesions of dioxin exposure: lessons from the poisoning of V. Yushchenko. Toxicol. Sci. 2012, 125:310-317.
67. Saurat J.H., Sorg O. Chloracne, a misnomer and its implications. Dermatology 2010, 221:23-26.
68. Schecter A.J., Sheu S.U., Birnbaum L.S., DeVito M.J., Denison M.S., Pa¨pke O. A comparison and discussion of two different methods of measuring dioxin-like compounds: gas chromatography-mass spectrometry and the CALUX bioassay F implications for health studies. Organohalogen Compd. 1999, 40:247-250.
69. Scheuplein R.J., Bowers J.C. Dioxin-an analysis of the major human studies: comparison with animal-based cancer risks. Risk Anal. 1995, 15:319-333.
70. Schmidt J.V., Bradfield C.A. Ah receptor signaling pathways. Annu. Rev. Cell Dev. Biol. 1996, 12:55-89.
71. Schnorr T.M., Lawson C.C., Whelan E.A., Dankovic D.A., Deddens J.A., Piacitelli L.A., Reefhuis J., Sweeney M.H., Connally L.B., Fingerhut M.A. Spontaneous abortion, sex ratio, and paternal occupational exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Environ. Health Perspect. 2001, 109:1127-1132.
72. Seefeld M.D., Corbett S.W., Keesey R.E., Peterson R.E. Characterization of the wasting syndrome in rats treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol. Appl. Pharmacol. 1984, 73:311-322.
73. Seifert A., Taubert H., Hombach-Klonisch S., Fischer B., Navarrete Santos A. TCDD mediates inhibition of p53 and activation of ERalpha signaling in MCF-7 cells at moderate hypoxic conditions. Int. J. Oncol. 2009, 35:417-424.
74. Sheu J.R. Pharmacological Effects of Rutaecarpine, an Alkaloid Isolated from Evodia rutaecarpa. Cardiovasc. Drug Rev. 1999, 17:237-245.
75. Shimba S., Hayashi M., Ohno T., Tezuka M. Transcriptional regulation of the AhR gene during adipose differentiation. Biol. Pharm. Bull. 2003, 26:1266-1271.
76. Simon T., Aylward L.L., Kirman C.R., Rowlands J.C., Budinsky R.A. Estimates of cancer potency of 2,3,7,8-tetrachlorodibenzo(p)dioxin using linear and nonlinear dose-response modeling and toxicokinetics. Toxicol. Sci. 2009, 112:490-506.
77. Sorg O., Zennegg M., Schmid P., Fedosyuk R., Valikhnovskyi R., Gaide O., Kniazevych V., Saurat J.H. 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) poisoning in Victor Yushchenko: identification and measurement of TCDD metabolites. Lancet 2009, 374:1179-1185.
78. Steele E.J., Bellett A.J., McCullagh P.J., Selinger B. Reappraisal of the findings on agent orange by the Australian royal commission. Toxicol. Lett. 1990, 51:261-268.
79. Streetman D.S., Bertino J.S., Nafziger A.N. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000, 10:187-216.
80. Swedenborg E., Pongratz I. AhR and ARNT modulate ER signaling. Toxicology 2010, 268:132-138.
81. Taylor J.S. Environmental chloracne: update and overview. Ann. N.Y. Acad. Sci. 1979, 320:295-307.
82. Thiess A.M., Frentzel-Beyme R., Link R. Mortality study of persons exposed to dioxin in a trichlorophenol-process accident that occurred in the BASF AG on November 17, 1953. Am. J. Ind. Med. 1982, 3:179-189.
83. Tian Y. Ah receptor and NF-kappaB interplay on the stage of epigenome. Biochem. Pharmacol. 2009, 77:670-680.
84. Tindall J.P. Chloracne and chloracnegens. J. Am. Acad. Dermatol. 1985, 13:539-558.
85. Trifari S., Kaplan C.D., Tran E.H., Crellin N.K., Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat. Immunol. 2009, 10:864-871.
86. Tuomisto J., Tuomisto J.T. Is the fear of dioxin cancer more harmful than dioxin?. Toxicol. Lett. 2012, 210:338-344.
87. Van den Berg M., Birnbaum L.S., Denison M., De Vito M., Farland W., Feeley M., Fiedler H., Hakansson H., Hanberg A., Haws L., Rose M., Safe S., Schrenk D., Tohyama C., Tritscher A., Tuomisto J., Tysklind M., Walker N., Peterson R.E. The 2005 World Health Organization reevaluation of human and Mammalian toxic equivalency factors for dioxins and dioxin-like compounds. Toxicol. Sci. 2006, 93:223-241.
88. Van den Berg M., De Jongh J., Poiger H., Olson J.R. The toxicokinetics and metabolism of polychlorinated dibenzo-p-dioxins (PCDDs) and dibenzofurans (PCDFs) and their relevance for toxicity. Crit. Rev. Toxicol. 1994, 24:1-74.
89. Villano C.M., Murphy K.A., Akintobi A., White L.A. 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces matrix metalloproteinase (MMP) expression and invasion in A2058 melanoma cells. Toxicol. Appl. Pharmacol. 2006, 210:212-224.
90. WHO Polychlorinated dibenzodioxins, polychlorinated dibenzofurans, and coplanar polychlorinated biphenyls. Safety Evaluation of Certain Food Additives and Contaminants 2002, WHO, Geneva.
91. Wincent E., Amini N., Luecke S., Glatt H., Bergman J., Crescenzi C., Rannug A., Rannug U. The suggested physiologic aryl hydrocarbon receptor activator and cytochrome P4501 substrate 6-formylindolo[3,2-b]carbazole is present in humans. J. Biol. Chem. 2009, 284:2690-2696.
92. Xiao Y., Xue X., Wu Y.F., Xin G.Z., Qian Y., Xie T.P., Gong L.K., Ren J. beta-Naphthoflavone protects mice from aristolochic acid-I-induced acute kidney injury in a CYP1A dependent mechanism. Acta Pharmacol. Sin. 2009, 30:1559-1565.
93. Yoshinari K., Ueda R., Kusano K., Yoshimura T., Nagata K., Yamazoe Y. Omeprazole transactivates human CYP1A1 and CYP1A2 expression through the common regulatory region containing multiple xenobiotic-responsive elements. Biochem. Pharmacol. 2008, 76:139-145.
94. Zudaire E., Cuesta N., Murty V., Woodson K., Adams L., Gonzalez N., Martinez A., Narayan G., Kirsch I., Franklin W., Hirsch F., Birrer M., Cuttitta F. The aryl hydrocarbon receptor repressor is a putative tumour suppressor gene in multiple human cancers. J. Clin. Invest. 2008, 118:640-650.